Cost-effectiveness analysis of hypertension treatment: Controlled release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension - The nifedipine and candesartan combination (NICE-Combi) study

Hypertension Research

Volumn 28, Issue 7, 2005, Pages 585-591

  Fujikawa, Keita ^b   Hasebe, Naoyuki ^a   Kikuchi, Kenjiro ^a   Takeda, Fumihiko ^c   Nakayama, Masaaki ^d   Aramaki, Jun ^e   Kimura, Mikako ^e   Takei, Akira ^e   Mitani, Masamitsu ^e   Ohno, Masaharu ^e   Nagano, Mitsunori ^f   Watanabe, Atsushi ^f   Yoshimatsu, Hidenori ^g   Masuda, Sumihiro ^g   Tsubaki, Koji ^g   Yamamoto, Tatsuki ^g   Tomiyasu, Yukihiro ^g   Muraoka, Shigenobu ^h   Ariyoshi, Michityasu ^h   Egashira, Keisuke ⁱ   Motomura, Akira ⁱ   Kusuhara, Hiroyuki ⁱ   Kawakami, Yasunobu ⁱ   Kubara, Ichiro ^j   Yamato, Hiroshi ^j   Hara, Keijiro ^j   Hirata, Yasuhiko ^k   Hirata, Miki ^k   Ikematsu, Wataru ^l   Yano, Kazutoshi ^m   Dohmen, Kazufumi ⁿ   Nagao, Haruhisa ^o   Nagao, Teisuke ^o   Ikematsu, Hideyuki ^p   Hayashi, Toshiko ^p   Uozumi, Yuki ^p   Kondo, Hiroko ^p   Ayukawa, Kasuo ^p   Nabeshima, Atsuko ^p   Tada, Hitoshi ^p   Tsuru, Tomomi ^q   Sasaki, Yasushi ^r   Yamanaga, Yoshiyuki ^r   Murakami, Atsushi ^r   Yamamoto, Munemitsu ^r   Mikasa, Michitaka ^r   Fujii, Shigeru ^s   Suzuki, Nobuyuki ^s   Miyazono, Hirotaka ^s   Hirabe, Toshiya ^s   Kiyoi, Kihou ^s   Yurino, Nobuo ^t   Akaike, Yuji ^t   Tsurusaki, Naokuni ^t   Kan, Yoshifumi ^t   Yoshimura, Toshio ^t   Tanaka, Shinichi ^t   Ura, Sachiko ^t   Kyoyama, Yasunori ^t   Ohsaka, Atsumi ^u   Mochinaga, Shunichi ^u   Yamashita, Naohiro ^u   Umezu, Toru ^v   Tanaka, Shigemachi ^w   Murakami, Hironori ^w   Hanawa, Nagisa ^w   Ohmoto, Yasuhiro ^w   Takada, Tamaki ^w   Yamaie, Hitoshi ^x   Aoki, Koichi ^x   Hamano, Yutaka ^y   Yamaguchi, Akiyuki ^z   Nagasaka, Fujio ^z   Hashimoto, Shu ^z   Nagakura, Toshikazu ^aa   Taniguchi, Masayuki ^aa   Taniguchi, Ikuo ^aa   Tomita, Fumishi ^ab   Kondo, Keiichi ^ab   more..

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b BAYER YAKUHIN LTD   (Japan)

^c Riverside Clinic of Internal Medicine and Cardiology   (Japan)

^d Swninoe Hospital   (Japan)

^e Yagi Hospital   (Japan)

^f Nishi Fukuoka Hospital   (Japan)

^g Mito Hospital   (Japan)

^h Ariyoshi Hospital   (Japan)

ⁱ Sakura Hospital   (Japan)

^j Hara Hospital   (Japan)

^k Hirata Clinic   (Japan)

^l Naika Clinic   (Japan)

^m Yano Clinic   (Japan)

ⁿ Okabe Hospital   (Japan)

^o Nagao Clinic   (Japan)

^p Hara Doi Hospital   (Japan)

^q Hataka Ekihigashi Clinic   (Japan)

^r FUKUOKA WAJIRO HOSPITAL   (Japan)

^s Chiyuukai Komonji Hospital   (Japan)

^t Yukuhashi Central Hospital   (Japan)

^u Kyomachi Naika Hospital   (Japan)

^v Umezu Clinic   (Japan)

^w Teine Keijinkai Clinic   (Japan)

^x Obase Hospital   (Japan)

^y Tawaramachi Hamano Hospital   (Japan)

^z Yamaguchi National Hospital   (Japan)

^aa Yoga Allergy Clinic   (Japan)

^ab Asahi Medical Clinic   (Japan)

more..

Author keywords

Candesartan; Controlled release nifedipine; Essential hypertension; Incremental cost effectiveness analysis

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; NIFEDIPINE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; FEMALE; FLUSHING; HEADACHE; HEALTH INSURANCE; HEART PALPITATION; HUMAN; JAPAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SIDE EFFECT; THORAX PAIN;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; COST-BENEFIT ANALYSIS; DELAYED-ACTION PREPARATIONS; DRUG COSTS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; JAPAN; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; NIFEDIPINE; TETRAZOLES;

EID: 25844449166     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.28.585     Document Type: Article

References (10)

1. Chobanian AV, Bakris GL, Black HR, et al: The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003; 289: 2560-2572.
2. World Health Organization (WHO)/International Society of Hypertension (ISH): 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983-1992.
3. Guideline Committee: 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
4. Guidelines Subcommittee: Guidelines for the Management of Hypertension for General Practitioners. Hypertens Res 2001; 24: 613-634.
5. Hasebe N, Kikuch K: Controlled Release Nifedipine and Candesartan Low-Dose Combination Therapy in Patients with Essential Hypertension: NICE Combi (Nifedipine and Candesartan Combination) Study. J Hypertens 2005; 23: 445-453.
6. Pitt B, Byingto RP, Furberg CD, for the PREVENT Investigators: Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102: 1503-1510.
7. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
8. Yui Y, Sumiyoshi T, Kodama K, et al: Nifedipine retard was as effective as angiotensin converting enzyme inhibitors in preventing cardiac events in high-risk hypertensive patients with diabetes and coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) subgroup analysis. Hypertens Res 2004; 27: 449-456.
9. Yui Y, Sumiyoshi T, Kodama K, et al, Japan Multicenter Investigation for Cardiovascular Diseases-B Study Group: Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res 2004; 27: 181-191.
10. Julius S, Kjeldsen SE, Weber M, et al, VALUE trial group: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004; 363: 2022-2031.